ABCA1 and atherosclerosis: Since the results herein our report do show that inhibiting miR-33a-5p does promote ABCA1-dependent cholesterol efflux in cultured MLC, these findings demonstrate, proof-of-concept, that specific inhibition of miR-33a-5p in MLC may have therapeutic implications in treating atherosclerosis.